India, Sept. 3 -- Eikon Therapeutics, Inc. (EIKN), a late-stage clinical biopharmaceutical company, on Thursday announced the appointment of Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer.
Chang joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President and Head of Cardiovascular Discovery Biology and Translational Pharmacology. Previously, he was Head of Cardiovascular Research at Gilead Sciences and Vice President of Disease Biology at MyoKardia.
At MyoKardia, Chang built a disease biology program focused on understanding and targeting the genetic causes of cardiomyopathies and the characterization of mavacamten, which was later approved by the FDA in 2022 for the treatment of hy...